Azịza ngwa ngwa
A monthly approval list tells a program sponsor nothing about their own sequence. It does not say whether the month's new products compete for the same synthes…
Kedu ihe FDA kwadoro na Septemba 2026, na Olee Otú E Si Kọwaa Ọnụ Ọgụgụ ahụ?
Onye nrụpụta Peptide N'ogbe Glp Peptide Nkwenye ọgwụ ọhụrụ itoolu na-ebu Septemba 2026 ụbọchị na Tebụlụ nkwado ọgwụ FDA maka 2026, na ibe ugbu a dị ka nke 9 October 2026. FDA na-akọwa ọgwụ ọhụrụ dị ka "ọgwụ ọhụrụ akwadobeghị ma ọ bụ ahịa na US." (Tebụlụ nkwado ọgwụ FDA maka 2026, ewepụtara 2026-10-09), nke mere na tebụl ahụ bụ ọnụ ọgụgụ a kapịrị ọnụ na warara.
Kedu n'ime nkwenye ndị ahụ bụ Peptides, Protein, Radioligands, Usoro ọgwụgwọ Gene, ma ọ bụ obere Molecules?
Ngwaahịa Radioligand na-egosi peptide-precursor, akara redio na ihe nkesa nwere mmetụta oge. Ntinye akwụkwọ ANDA abụghị nkwado, na a 505(b)(2) ngwa abụghị ANDA. Nyochaa nkwado ngwaahịa ọ bụla na ndụ nchekwa site na ndekọ FDA nke ya kama ịnyefe akara Lutathera na ngosi ọzọ..
Malite na ntinye abụọ ahụ na-ele anya peptide n'akụkụ na ọ bụghị. Apitegromab bụ ihe mgbochi CHO gosipụtara, ọ bụghị sịntetik peptide: IgG4 lambda zuru oke nke mmadụ emepụtara na mkpụrụ ndụ ovary hamster nke China n'oge siri ike 147 kDa (Isembyld na-edepụta ozi, 11 Septemba 2026). Insulin efsitora alfa bụ ihe analọgụ insulin Fc-fusion karịa nke a na-ahụkarị Polypeptide Synthesis peptide, sitere na insulin nwere otu agbụ, njikọ abụọ na mpaghara IgG2 Fc mmadụ na 299 residues kwa monomer na ihe dị ka 64 kDa (Onswik na-edepụta ozi, 23 Septemba 2026). Oke ọnụ ọgụgụ fọdụrụnụ nke na-ekewa peptide na protein ngwakọta na-anọdụ ala 50 amino asịd, ojiji IUPAC na FDA na-eme ka Fc-fusion bụrụ protein.
Enwere nkwenye ọgwụ Peptide ọhụrụ na Septemba, na Gịnị bụ akara ngosi Peptide dị mkpa?
Ọnụọgụ usoro kwa ọnwa enweghị ike igosipụta usoro a na-achọ maka nrụpụta sịntetik-peptide. Protein peptide metụtara recombinant na peptide radioligands na-ewelitekwa ajụjụ mmepụta dị iche iche site na ihe ọhụrụ na-arụ ọrụ peptide na-arụ ọrụ nke kemịkal..
Peptides Suppliers Onye nrụpụta Nyocha 1 Peptides
Kedu ka onye isi CMC kwesịrị isi gụọ ndepụta nnabata kwa ọnwa mgbe ị na-eme atụmatụ inye Peptide?
Gụọ kọlụm ụzọ n'ihu kọlụm ngwaahịa, n'ihi na ụzọ na-ebu amụma ngwugwu nyocha a ga-arịọ mmemme peptide ka ọ kwado. Ọnụ ụzọ European Pharmacopoeia etinyere site na ntuziaka peptides synthetic nke EMA chọrọ mkpesa n'elu. 0.1%, njirimara n'elu 0.5% na iru eru n'elu 1.0%, na ngalaba-ekpochapụ adịghị ọcha na-ejide 1.0% oke iru eru (EMA synthetic peptides ntuziaka, mbipụta ugbu a). Ihe peptides sịntetik na-anọdụ n'èzí ICH Q3A kpuchie, Ya mere, onye na-eweta ihe na-ehota Q3A maka profaịlụ adịghị ọcha peptide na-ezo aka na akwụkwọ na-ezighi ezi.
Nkwekọrịta abụọ ọzọ na-esote site n'otu ọgụgụ ahụ. Nkwado kwesịrị iso ICH Q2(R2), nakweere na Nzọụkwụ 4 na 1 Nọvemba 2023, nke maka ule adịghị ọcha nke quantitative na-ekpuchikarị nkọwapụta, oke, obere oke oke, izi ezi na nkenke (I Q2(R2), 2023). Nkwụsi ike kwesịrị izute opekempe ogologo oge ọnwa iri na abụọ na ọnwa isii agbatịkwuru na opekata mpe atọ mbụ., na ngwaahịa refrigerated nke 5°C gbakwunyere ma ọ bụ mwepu 3°C (I Q1A(R2), 2003). Oke Endotoxin maka peptide parenteral na-agbaso usoro K/M, na K na 5 USP-EU/kg maka ụzọ ọ bụla na-abụghị intrathecal (USP General Isi <85>, USP 35 ederede). Njirimara nyocha peptide bụ ebe a na-anwale akwụkwọ ndị a, na ndepụta kwa ọnwa dị mkpa naanị ma ọ bụrụ na ọ gbanwere nke n'ime ha mmemme ga-emeju afọ.
Ekwesịrị ịgụ nha ahịa n'otu ụzọ ahụ. Grand View Research na-eme atụmatụ na 2025 ahịa ọgwụgwọ peptide na $140.9B, a na-eme ya site na insulin, A na-agụta ụdị GLP-1 na mpaghara ala dị iche iche (Nchọpụta Nleba anya, 2026). Ndekọ nnabata peptide Purdue, nke bara uru 51 ihe na-arụ ọrụ na 92 òtù nkwado, na-eburu ọkwa nke ya na ọnụ ọgụgụ ndị ahụ anaghị egosipụta nkwado FDA ochie ma ọ bụ ihe akaebe ndị ọzọ nke US. ahịa (CD, Mahadum Purdue, emechiri emechi). Ọgwụ nke Octreotide 23 ngwa niile megide 4 Ndị na-emepụta ihe ọhụrụ na ndeksi ahụ bụ akara kacha pụta ìhè na ụmụ irighiri ihe peptide tozuru oke na-aghọ otu ìgwè mmadụ ebe usoro ọhụrụ na-abata dị ka otu nkwenye.. Ndị na-eweta Peptides
Ajụjụ a na-ajụkarị
A kwadoro peptide ọ bụla na Septemba 2026?
Ọ nweghị peptide NME ọhụrụ pụtara na Septemba 2026 setịpụrụ. Ndenye abụọ kacha nso, apitegromab na insulin efsitora alfa, bụ ihe mgbochi IgG4 CHO gosipụtara yana protein Fc-fusion n'otu n'otu (Onswik na-edepụta ozi, 23 Septemba 2026).
Ọ na-egosi ọnwa efu-peptide na-adaba agụụ peptide?
Mba. FDA kwadoro otu peptide n'ime ha niile 2025, elamipretide na 19 Septemba (2025 FDA TIDES owuwe ihe ubi, 30 Jenụwarị 2026). Ihe efu nke otu ọnwa anaghị ebu usoro ọ bụla.
Mmechi
Nzọụkwụ ọzọ bara uru bụ ịme otu usoro na mmepe wee mapụ ya megide akwụkwọ ndị dị n'elu: nke 0.1, 0.5 na 1.0 pasent adịghị ọcha, ICH Q2(R2) ntọala nkwado, opekempe nkwụsi ike nke ọnwa iri na abụọ na ọnwa isii, na oke K/M endotoxin. Ọ bụrụ na ngwugwu data onye na-ebubata enweghị ike ịza isi ihe anọ ahụ, ndepụta nkwado kwa ọnwa abụghị ihe mgbochi.
Banyere onye nkwusa. MOL Changes bụ nyocha na nzukọ mmepe na-enye ọrụ peptide, site na nhazi usoro omenala na mmepụta ihe dị ukwuu, ya mere ọ nwere mmasị azụmahịa n'otú ọchịchọ mmepụta peptide si amalite. Ndị na-agụ akwụkwọ kwesịrị iji nke ahụ n'uche tụlee echiche ya. Ntuziaka dị n'elu anaghị adabere na ọrụ ya.
